Is acute rejection deleterious to long-term liver allograft function?

Journal of Hepatology

Volumn 29, Issue 4, 1998, Pages 660-668

  Dousset, Bertrand ^a   Conti, Filomena ^a   Cherruau, Brigitte ^a   Louvel, Albert ^a   Soubrane, Olivier ^a   Houssin, Didier ^a   Calmus, Yvon ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

Acute rejection; BSP clearance; Graft function; ICG clearance; Liver transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BROMSULFOPHTHALEIN; GAMMA GLUTAMYLTRANSFERASE;

ADOLESCENT; ADULT; ALLOGRAFT; ARTICLE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032191719     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80163-3     Document Type: Article

References (42)

1. 1. Adams DH, Neuberger JM. Patterns of graft rejection following liver transplantation. J Hepatol 1990; 10: 113-9.
2. 2. Cherqui D, Duvoux C, Charlotte F, Humeres R, Lauzet JY, Metreau JM, et al. Intérêt d'une forte immunosuppression initiale après transplantation hépatique. Etude prospective de 60 cas. Gastroenterol Clin Biol 1994; 18: 115-22.
3. 3. Klintmalm GBG, Nery JR, Husberg BS, Gonwa TA, Tillery GW. Rejection in liver transplantation. Hepatology 1989; 10: 978-85.
4. 4. Mor E, Solomon H, Gibbs JF, Holman MJ, Goldstein RM, Husberg BO, et al. Acute cellular rejection following liver transplantation: clinical pathologic features and effect on outcome. Semin Liver Dis 1992; 12 : 28-40.
5. 5. Dousset B, Hubscher SG, Padbury RTA, Gunson BK, Buckels JAC, Mayer AD, et al. Acute liver allograft rejection - is treatment always necessary? Transplantation 1993; 55: 529-34.
6. 6. Conti F, Dousset B, Archambeau D, Louvel A, Houssin D, Calmus Y. Enhanced risk of steroid-resistant acute rejection following pretransplant steroid therapy in liver graft recipients. Transplantation 1995; 60: 1104-8.
7. 7. Busuttil RW, Shaked A, Millis JM, Jurim O, Colquhoum SD, Shakleton CR, et al. One thousand liver transplants: the lessons learned. Ann Surg 1994; 219: 490-9.
8. 8. Quiroga J, Colina I, Demetris AJ, Starzl TE, Van Thiel DH. Cause and timing of first allograft failure in orthotopic liver transplantation: a series of 177 consecutive patients. Hepatology 1991; 14: 1054-61.
9. 9. Shaw BW, Wood RP, Stratta RJ, Pillen TJ, Langnas AN. Stratifying the cause of death in liver transplant recipients. An approach to improving survival. Arch Surg 1989; 124: 895-900.
10. 10. Kalayoglu M, Sollinger HW, Stratta RJ, D'Alessandro AM, Hoffmann RM, Pirsch JD, et al. Extended preservation of the liver for clinical transplantation. Lancet 1988; i: 617-9.
11. 11. Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323-8.
12. 12. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-7.
13. 13. Vaubourdolle M, Gufflet V, Chazouillères O, Giboudeau J, Poupon R. Indocyanin green-sulfobromophthalein pharmacokinetics for diagnosing primary biliary cirrhosis and assessing histological severity. Clin Chem 1991; 37: 1688-91.
14. 14. Pillay D, Charman H, Burroughs AK, Smith M, Rolles K, Griffiths PD. Surveillance for CMV infection in orthotopic liver transplant recipients. Transplantation 1992; 53: 1261-5.
15. 15. Hubscher SG. Histological findings in liver allograft rejection. New insights in the pathogenesis of hepatocellular damage in liver allografts. Histopathology 1991; 18: 377-83.
16. 16. Soloway RD, Baggenstoss AH, Schoenfield W, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Dig Dis Sci 1971; 16: 1082-6.
17. 17. Bedossa P, Poynard T, and the METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
18. 18. Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 1961; 21: 43-57.
19. 19. Clements D, McMaster, Elias E. Indocyanine green clearance in acute rejection after liver transplantation. Transplantation 1988; 46: 383-5.
20. 20. Jalan R, Plevris JN, Jalan AR, Finlayson NDC, Hayes PC. A pilot study of indocyanine green clearance as an early predictor of graft function. Transplantation 1994; 58: 196-200.
21. 21. Paumgartner G. The handling of indocyanine green by the liver. Schweiz Med Wochenschr 1975; Suppl: 3-30.
22. 22. Meijer DKF, Blom A, Weitering JG, Hornsveld R. Pharmacokinetics of the hepatic transport of organic anions: influence of extra-and intracellular binding on hepatic storage of dibromosulfophthalein and interactions with indocyanine green. J Pharmacokinet Biopharm 1984; 12: 43-65.
23. 23. Keiding S. Hepatic clearance and liver blood flow. J Hepatol 1987; 4: 393-398.
24. 24. Carson E, Jones A. Use of kinetic analysis and mathematical modeling in the study of metabolic pathways in vivo. N Engl J Med 1979; 300: 1078-1086.
25. 25. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992; 51: 229-38.
26. 26. Reichen J. MEGX test in hepatology: The long-sought ultimate quantitative liver function test? J Hepatol 1993; 19: 4-7.
27. 27. Van Hoek B, Wiesner RH, Krom RAF, Ludwig J, Moore SB. Severe ductopenic rejection following liver transplantation: incidence, time of onset, risk factors, treatment, and outcome. Semin Liver Dis 1992; 12: 41-50.
28. 28. Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992; 16: 865-76.
29. 29. Freeman RB, Tran S, Lee YM, Rohrer RJ, Kaplan MN. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis. Transplantation 1996; 61: 542-6.
30. 30. Houssin D, Soubrane O, Boillot O, Dousset B, Ozier Y, Devictor D, et al. Orthotopic liver transplantation with a reduced-size graft: an ideal compromise in pediatrics. Surgery 1992; 111: 532-42.
31. 31. Kawasaki S, Makuuchi M, Ishizone S, Matsunami H, Terada M, Kawarazaki H. Liver regeneration in recipients and donors after transplantation. Lancet 1992; 339: 580-1.
32. 32. Dousset B, Filipponi F, Soubrane O, Boillot O, Houssin D, Chapuis Y. Partial hepatic resection for ischemic graft damage after liver transplantation: a graft-saving option? Surgery 1994; 115: 540-5.
33. 33. Francavilla A, Barone M, Todo S, Zeng Q, Porter QA, Starzl TE. Augmentation of rat liver regeneration by FK506 compared with cyclosporin. Lancet 1989; i: 1248-9.
34. 34. Kahn D, Makowka L, Lai H, Eagon PK, Dindzans V, Starzl TE, et al. Cyclosporine augments hepatic regenerative response in rats. Dig Dis Sci 1990; 35: 392-8.
35. 35. Mazzafero V, Porter KA, Scotti-Foglieni CL, Venkataramanan R, Makowka L, Rossaro L, et al. The hepatotropic influence of cyclosporine. Surgery 1990; 107: 533-9.
36. 36. Kawanao K, Kim Y, Kaketani K, Kobayashi M. The beneficial effect of cyclosporin on liver ischemia in rats. Transplantation 1989; 49: 759-64.
37. 37. Dhar DK, Nagasue N, Kimoto T, Uchida M, Takemoto Y, Nakamura T. The salutary effect of FK 506 in ischemia-reperfusion injury of the canine liver. Transplantation 1992; 54: 583-8.
38. 38. Padbury RTA, Gunson BK, Dousset B, Hubscher SG, Buckels JAC, Neuberger JM, et al. Steroid withdrawal from long term immunosuppression in liver allograft recipients. Transplantation 1993; 55: 789-94.
39. 39. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323: 1767-9.
40. 40. Farge D and the collaborative Transplantation Research Group of Ile de France. Kaposi's sarcoma in organ transplant recipients. Eur J Med 1993; 2: 339-43.
41. 41. Reding R, Wallemack PE, Lamy ME, Rahier J, Sempoux C, Debande B, et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Transplantation 1994; 57: 93-100.
42. 42. Demetris AJ, Fung JJ, Todo S, McCauley J, Jain A, Takaya S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: a clinicopathologic study of 96 patients. Transplantation 1992; 53: 1056-62.